Addiction Medications Table
Week 6
THIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 6 MEDICATION TABLE DROPBOX BY SUNDAY AT 11:59 P.M. MT.
Drug Name Indication Half-life (T1/2), Notable Side Effects Initial Dosing
Neurotransmitter(s) Metabolism (CYP 450 (link to NT or affected Considerations
Affected enzyme) brain circuit) Specific lifespan
Target Symptoms considerations
(age, pregnancy,
breastfeeding)
Buprenorphine Indication: 24-42 Headache, Initial dosing:
(Subutex) Maintenance hours constipation, nausea Sublingual 8-32
treatment of opioid CYP450: Oral hypoesthesia, mg/day
dependence CYP3A4 glossodynia
Maintenance 24-42 Orthostatic Controlled studies
treatment of opioid hours hypotension have not been
dependence in CYP450: Respiratory distress conducted in
patients who have CYP3A4 Hepatotoxicity pregnant women.
achieved and Half-life: 24-42 hours Buprenorphine
sustained prolonged CYP450: CYP3A4 Binds to mu opioid may be preferable
clinical stability on receptors to methadone in
low-to moderate pregnant women.
doses of a trans Neonatal opioid
mucosal withdrawal
buprenorphine syndrome has been
containing product reported following
Moderate to severe use of
opioid use disorder in Buprenorphine
patients who have during pregnancy
initiated treatment
with a transmucosal Some drug is
Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.
, Addiction Medications Table
Week 6
buprenorphine found in mother’s
containing product, breast milk.
followed by dose Recommended
adjustment for a either to
minimum of 7 days discontinued drug
or formula feed.
Neurotransmitter
affected: Mu opioid Use with caution
receptor partial in elderly. Some
agonist Antagonist at patients may
the kappa opioid tolerate lower
receptor doses better.
Target symptoms:
Opioid dependence
Buprenorphine/Naloxone Indication: Suboxone: 24-42 hours Headache, Initial dosing:
(Suboxone, Zubsolv, Treatment, and Naloxone: 2-12 hours constipation, nausea, Bunavail: Day 1:
Bunavail) maintenance of CYP450: CYP3A4 oral hypoesthesia, induction dose:
opioid dependence. glossodynia, Initial: Buccal:
orthostatic Buprenorphine 2.1
Induction of hypotension, sedation mg/naloxone 0.3
treatment for opioid mg; may repeat
dependence Binding at mu opioid dose after 2 hours,
Maintenance receptors based on control of
treatment of opioid acute withdrawal
dependence in symptoms;
patients who have maximum total
achieved and dose:
sustained prolonged buprenorphine 4.2
clinical stability on mg/naloxone 0.7
low-to moderate mg. Day 2:
Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.
Week 6
THIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 6 MEDICATION TABLE DROPBOX BY SUNDAY AT 11:59 P.M. MT.
Drug Name Indication Half-life (T1/2), Notable Side Effects Initial Dosing
Neurotransmitter(s) Metabolism (CYP 450 (link to NT or affected Considerations
Affected enzyme) brain circuit) Specific lifespan
Target Symptoms considerations
(age, pregnancy,
breastfeeding)
Buprenorphine Indication: 24-42 Headache, Initial dosing:
(Subutex) Maintenance hours constipation, nausea Sublingual 8-32
treatment of opioid CYP450: Oral hypoesthesia, mg/day
dependence CYP3A4 glossodynia
Maintenance 24-42 Orthostatic Controlled studies
treatment of opioid hours hypotension have not been
dependence in CYP450: Respiratory distress conducted in
patients who have CYP3A4 Hepatotoxicity pregnant women.
achieved and Half-life: 24-42 hours Buprenorphine
sustained prolonged CYP450: CYP3A4 Binds to mu opioid may be preferable
clinical stability on receptors to methadone in
low-to moderate pregnant women.
doses of a trans Neonatal opioid
mucosal withdrawal
buprenorphine syndrome has been
containing product reported following
Moderate to severe use of
opioid use disorder in Buprenorphine
patients who have during pregnancy
initiated treatment
with a transmucosal Some drug is
Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.
, Addiction Medications Table
Week 6
buprenorphine found in mother’s
containing product, breast milk.
followed by dose Recommended
adjustment for a either to
minimum of 7 days discontinued drug
or formula feed.
Neurotransmitter
affected: Mu opioid Use with caution
receptor partial in elderly. Some
agonist Antagonist at patients may
the kappa opioid tolerate lower
receptor doses better.
Target symptoms:
Opioid dependence
Buprenorphine/Naloxone Indication: Suboxone: 24-42 hours Headache, Initial dosing:
(Suboxone, Zubsolv, Treatment, and Naloxone: 2-12 hours constipation, nausea, Bunavail: Day 1:
Bunavail) maintenance of CYP450: CYP3A4 oral hypoesthesia, induction dose:
opioid dependence. glossodynia, Initial: Buccal:
orthostatic Buprenorphine 2.1
Induction of hypotension, sedation mg/naloxone 0.3
treatment for opioid mg; may repeat
dependence Binding at mu opioid dose after 2 hours,
Maintenance receptors based on control of
treatment of opioid acute withdrawal
dependence in symptoms;
patients who have maximum total
achieved and dose:
sustained prolonged buprenorphine 4.2
clinical stability on mg/naloxone 0.7
low-to moderate mg. Day 2:
Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.
